Drugs / zamicastat
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06009185 | Jun 2019 → Feb 2022 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 2 | NCT04316143 | Jun 2019 → Oct 2021 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zamicastat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04316143 ↗ |
| Action | Inhibit | “Dopamine beta-hydroxylase inhibitor” CHEMBL4594440 ↗ |
| Modality | Small molecule | — CHEMBL4594440 ↗ |
| Route | Oral | “Tablets for oral administration under fed conditions containing 100 mg of zamicastat” NCT04316143 ↗ |
| Target | DBH | “Dopamine beta-hydroxylase inhibitor” CHEMBL4594440 ↗ |